MedTrace Logo

Open-label V565 Target Engagement Study

NCT03705117 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-10-15

No results posted yet for this study

Summary

The purpose of the study is to confirm that V565 enters inflamed tissue, binds to TNF and reduces inflammation after oral dosing to patients with IBD.

Conditions

Interventions

BIOLOGICAL

V565

Capsules for oral administration

Sponsors & Collaborators

  • VHsquared Ltd.

    lead INDUSTRY

Principal Investigators

  • Suhail Nurbhai, MBChB · VHsquared Ltd.

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-23
Primary Completion
2017-10-24
Completion
2017-10-24

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03705117 on ClinicalTrials.gov